We have previously shown an adverse effects of ex vivo measured anti-CEA TH1 responses on post-operative CRC patient outcome.1 In this previous study, we did not measure IL-17A responses, which require a period of in vitro culture and expansion. The gene discussed is IL17A; the disease is colorectal carcinoma.